Aspects of the Safe Use of Antibacterial Drugs in Community-Acquired Pneumonia: the Implications of Drug-Drug Interactions

QR Code

Aspects of the Safe Use of Antibacterial Drugs in Community-Acquired Pneumonia: the Implications of Drug-Drug Interactions

Background. Drug-drug interactions can seriously affect the safety profile of a drug and are an important problem worldwide. Due to the aging of the population, the increasing frequency of polypharmacy, as well as the spread of self-medication, adverse events that are difficult to identify may occur...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	A. A. Taube, B. K. Romanov, E. V. Shubnikova, R. N. Alyautdin, M. V. Zhuravleva, O. A. Demidova, E. Yu. Demchenkova
Hōputu:	Tuhinga
Reo:	Ruhiana
I whakaputaina:	LLC "Publishing House OKI" 2022-08-01
Rangatū:	Антибиотики и Химиотерапия
Ngā marau:	drug-drug interactions community-acquired pneumonia drug safety antibacterial drugs adverse reaction pharmacovigilance
Urunga tuihono:	https://www.antibiotics-chemotherapy.ru/jour/article/view/913
Tags:	Tāpirihia he Tūtohu No Tags, Be the first to tag this record!

Ngā tūemi rite

Comparative Analysis of Drug Interactions with Antibacterial Agents in the Treatment of Community-Acquired Pneumonia
mā: A. A. Taube, me ētahi atu.
I whakaputaina: (2021-10-01)

Antibacterial Therapy of Severe Community-Acquired Pneumonia in Adults - Is There a Need for New Drugs?
mā: S. A. Rachina, me ētahi atu.
I whakaputaina: (2020-05-01)

Evaluation of the Efficacy and Safety of Initial Empirical Antibiotic Therapy for Community-Acquired Pneumonia in Middle-Aged People
mā: T. V. Alexandrova, me ētahi atu.
I whakaputaina: (2022-07-01)

Role of Pharmacovigilance in Drug Safety Monitoring
mā: Anju E. Paul, me ētahi atu.
I whakaputaina: (2025-07-01)

International Drug Safety Monitoring
mā: A. S. Kazakov, me ētahi atu.
I whakaputaina: (2019-09-01)

Methodology for Creating a Risk Management System for Drug-Drug Interactions
mā: A. A. Taube, me ētahi atu.
I whakaputaina: (2024-03-01)

EVALUATION OF SAFETY OF DRUG THERAPY IN CLINICAL PRACTICE
mā: M. N. Kostyleva, me ētahi atu.
I whakaputaina: (2015-03-01)

Drug Safety Monitoring Information
mā: E. V. Shubnikova, me ētahi atu.
I whakaputaina: (2021-07-01)

Topical Issues of Drug Safety, Possibilities of Improving of Pharmacovigilance
mā: M. V. Zhuravleva, me ētahi atu.
I whakaputaina: (2019-09-01)

Review of publications on drug-related problems investigations in osteoporosis patients
mā: E. A. Egorova, me ētahi atu.
I whakaputaina: (2024-01-01)

Rational Organisation of Adverse Drug Reaction Monitoring
mā: L. V. Shukil, me ētahi atu.
I whakaputaina: (2022-10-01)

Problematic aspects of participation of pharmacists in the system of pharmacovigilance in Russia
mā: E. N. Tkhoseva, me ētahi atu.
I whakaputaina: (2022-06-01)

Validation of Drug Resistance in Pneumonia (DRIP) Score as Empirical Antibiotic Failure Predictor in Community-Acquired Pneumonia Patients in Cipto Mangunkusumo Hospital
mā: Rohayat Bilmahdi Simanjuntak, me ētahi atu.
I whakaputaina: (2024-04-01)

Adverse Reactions of Drugs Containing Valeriana and Corvalol: Analysis of Spontaneous Reporting
mā: S. L. Morokhina, me ētahi atu.
I whakaputaina: (2018-12-01)

Drug Safety Monitoring—International Information
mā: E. V. Shubnikova, me ētahi atu.
I whakaputaina: (2020-12-01)

Monitoring of drug safety
mā: B. K. Romanov, me ētahi atu.
I whakaputaina: (2022-06-01)

Safety of Antibacterial and Antiprotozoal Medicinal Products
mā: E. V. Shubnikova, me ētahi atu.
I whakaputaina: (2022-07-01)

Postmarketing Surveillance: Review of Open Sources of Drug Safety Data
mā: E. V. Shubnikova
I whakaputaina: (2024-10-01)

ON THE ISSUE OF SAFETY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
mā: N. Yu. Velts, me ētahi atu.
I whakaputaina: (2018-09-01)

Review of the monograph by Kolbin A. S., Zyryanov S. K., Belousov D. Yu. "Pharmacovigilance" 2025
mā: V. I. Petrov
I whakaputaina: (2025-01-01)

Monitoring Drug Safety Information - Recommendations of Foreign Regulatory Authorities
mā: Elena V. Shubnikova, me ētahi atu.
I whakaputaina: (2020-03-01)

The Adverse Drug Reactions Registered During the Postmarketing Period
mā: E. V. Shubnikova, me ētahi atu.
I whakaputaina: (2019-03-01)

What is the role of antineoplastic drug safety in reimbursement decision making?
mā: A. S. Kolbin, me ētahi atu.
I whakaputaina: (2018-11-01)

The potential of methylethylpiridinol in treatment of bacterial infections caused by Klebsiella pneumoniae (experimental study)
mā: V. M. Brykhanov, me ētahi atu.
I whakaputaina: (2016-10-01)

Retrospective Analysis of the Safety of Antibacterial Medicinal Products for Elderly Patients with Community-Acquired Lower Respiratory Tract Infections
mā: G. I. Gorodetskaya, me ētahi atu.
I whakaputaina: (2023-03-01)

COMPARATIVE REVIEW OF METHODOLOGIES FOR ESTIMATING THE COST OF ADVERSE DRUG REACTIONS IN THE RUSSIAN FEDERATION AND BRAZIL
mā: G. I. Syraeva, me ētahi atu.
I whakaputaina: (2021-03-01)

Drug-Induced Neutropenia and Agranulocytosis
mā: O. D. Ostroumova, me ētahi atu.
I whakaputaina: (2020-09-01)

Comparative Analysis of International Databases of Adverse Drug Reactions
mā: A. S. Kazakov, me ētahi atu.
I whakaputaina: (2020-09-01)

EVALUATIONS OF ADVERSE DRUGS REACTIONS IN RUSSIA IN 2013
mā: V. A. Merkulov, me ētahi atu.
I whakaputaina: (2022-05-01)

IS THE PATIENT PARTNERSHIP INFORMATIVE IN PHARMACOVIGILANCE?
mā: Yu. V. Muravyev
I whakaputaina: (2017-09-01)

Levofloxacin: Analysis of Information on Adverse Reactions from Russian Spontaneous Report Database
mā: S. K. Zyryanov, me ētahi atu.
I whakaputaina: (2020-05-01)

MONITORING OF DRUG SAFETY IN CLINICAL PRACTICE
mā: N. V. Verlan, me ētahi atu.
I whakaputaina: (2017-02-01)

Clinical and pharmacological monitoring of drug safety in pediatrics
mā: N. V. Verlan, me ētahi atu.
I whakaputaina: (2016-05-01)

Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia
mā: V. G. Deriushkin, me ētahi atu.
I whakaputaina: (2021-02-01)

Fluoroquinolone antibiotics: safety of use by the example of ciprofloxacin
mā: N. V. Molchan, me ētahi atu.
I whakaputaina: (2019-06-01)

Spontaneous Adverse Drug Reaction Reporting of Congenital Malformations: A Danish National Register Study
mā: Ulrik Lausten-Thomsen, me ētahi atu.
I whakaputaina: (2025-06-01)

MODERN MODEL FORMATION OF DRUG PROVISION OF PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA IN KABARDINO-BALKARIA
mā: A. A. Umirova, me ētahi atu.
I whakaputaina: (2019-07-01)

Current Information on the Safety of Medicinal Products: Decisions of Foreign Regulatory Authorities
mā: E. V. Shubnikova
I whakaputaina: (2024-04-01)

Atrial Fibrillation Associated with Anticancer Drugs
mā: O. D. Ostroumova, me ētahi atu.
I whakaputaina: (2020-12-01)

Inhaled Polymyxin in Treatment of Elderly Patients with Severe Community-Acquired Klebsiella pneumoniae-Induced Pneumonia
mā: V. I. Sakharov, me ētahi atu.
I whakaputaina: (2020-12-01)